On this page
Proparacaine Hydrochloride
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Proparacaine Hydrochloride | 5 mg/mL | 1247445 | — |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Local Anesthesia [PE] | PE | All 53 members |
| Local Anesthetic [EPC] | EPC | 1 member — no class page |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 040074-001 | PROPARACAINE HYDROCHLORIDE | SOLUTION/DROPS | PROPARACAINE HYDROCHLORIDE | Prescription | AT | RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 11 | Manufacturing (CMC) | Approved | November 27, 2001 | — |
| Supplement | 10 | Manufacturing (CMC) | Approved | March 7, 2001 | — |
| Supplement | 9 | Manufacturing (CMC) | Approved | October 5, 2000 | — |
| Supplement | 8 | Manufacturing (CMC) | Approved | June 27, 2000 | — |
| Supplement | 5 | Manufacturing (CMC) | Approved | May 18, 2000 | — |
| Supplement | 7 | Manufacturing (CMC) | Approved | May 15, 2000 | — |
| Supplement | 6 | Manufacturing (CMC) | Approved | April 28, 2000 | — |
| Supplement | 4 | Manufacturing (CMC) | Approved | June 7, 1999 | — |
| Supplement | 3 | Manufacturing (CMC) | Approved | November 19, 1998 | — |
| Supplement | 2 | Manufacturing (CMC) | Approved | July 23, 1998 | — |
| Supplement | 1 | Labeling | Approved | July 23, 1998 | — |
| Original application | 1 | Approved | September 29, 1995 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260424). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Proparacaine Hydrochloride Ophthalmic solution is indicated for topical anesthesia in ophthalmic practice. Representative ophthalmic procedures in which the preparation provides good local anesthesia include measurement of intraocular pressure (tonometry), removal of foreign bodies and sutures from the cornea, conjunctival scraping in diagnosis and gonioscopic examination; it is also indicated for use as a topical anesthetic prior to surgical operations such as cataract extraction.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Usual Dosage: Removal of foreign bodies and sutures, and for tonometry: 1 to 2 drops (in single instillations) in each eye before operating. Short corneal and conjunctival procedures: 1 drop in each eye every 5 to 10 minutes for 5 to 7 doses. NOTE: Proparacaine hydrochloride ophthalmic solution USP, 0.5% should be clear, colorless to faint yellow color. If the solution becomes darker, discard the solution. FOR TOPICAL OPHTHALMIC USE ONLY
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Proparacaine hydrochloride ophthalmic solution should be considered contraindicated in patients with known hypersensitivity to any of the ingredients of this preparation.
Warnings
openFDA Drug LabelingWARNINGS NOT FOR INJECTION INTO THE EYE - For topical ophthalmic use only. Prolonged use of a topical ocular anesthetic may produce permanent corneal opacification with accompanying loss of vision. Proparacaine ophthalmic solution is indicated for administration under the direct supervision of a healthcare provider. Proparacaine ophthalmic solution is not intended for patient self-administration.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS Pupillary dilation or cycloplegic effects have rarely been observed with proparacaine hydrochloride. The drug appears to be safe for use in patients sensitive to other local anesthetics, but local or systemic sensitivity occasionally occurs. Instillation of proparacaine in the eye at recommended concentration and dosage usually produces little or no initial irritation, stinging, burning, conjunctival redness, lacrimation or increased winking. However, some local irritation and stinging may occur several hours after the instillation. Rarely, a severe, immediate-type, apparently hyperallergic corneal reaction may occur which includes acute, intense and diffuse epithelial keratitis; a gray, ground glass appearance; sloughing of large areas of necrotic epithelium; corneal filaments and, sometimes, iritis with descemetitis. Allergic contact dermatitis with drying and fissuring of the fingertips has been reported. Softening and erosion of the corneal epithelium and conjunctival congestion and hemorrhage have been reported. To report SUSPECTED ADVERSE REACTIONS, contact Somerset Therapeutics, LLC at 1- 800-417-9175 or FDA at 1-800 -FDA-1088 or www.fda.gov/medwatch
Description
openFDA Drug LabelingDESCRIPTION Proparacaine hydrochloride ophthalmic solution USP, 0.5% is a local anesthetic for ophthalmic instillation. Each mL of sterile aqueous solution contains active ingredient: proparacaine hydrochloride 5 mg (0.5%) and inactive ingredients: glycerin (tonicity agent), benzalkonium chloride, 0.01% (preservative) and water for injection (vehicle). The pH may be adjusted with hydrochloric acid and/or sodium hydroxide. At the time of manufacture, the air in the container is replaced by nitrogen. Proparacaine hydrochloride is designated chemically as 2-(Diethylamino) ethyl 3-amino-4-propoxybenzoate monohydrochloride. Graphic formula: C 16 H 26 N 2 O 3 •HCl MW 330.85 CAS-5875-06-9 proparacaine-stru
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Proparacaine hydrochloride ophthalmic solution USP, 0.5% is supplied in a low density polyethylene white bottle with a natural dropper tip with a white screw cap in the following size: NDC 70756-193-35 15 mL bottle in carton. Storage: Refrigerate at 2°C to 8° C (36°F to 46°F). Keep bottle tightly closed. Store bottles in carton until empty to protect from light. If solution shows more than a faint yellow color, it should not be used. DO NOT USE IF TAMPER-EVIDENT SEAL IS BROKEN OR MISSING. Keep out of reach of children. Manufactured for: Lifestar Pharma LLC 1200 MacArthur Blvd. Mahwah, NJ 07430 USA Product of Switzerland Revised: July 2024, V-02
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: PROPARACAINE HYDROCHLORIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Recalls
Source: FDA Enforcement| Classification | Reported | Firm | Reason | Status |
|---|---|---|---|---|
| Class II | October 2, 2024 | Mckesson Medical-Surgical Inc. Corporate Office | Temperature abuse: Products exposed to improper temperature above drug label specifications. | Terminated |
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 50090-1923-0 | 50090-1923 | A-S Medication Solutions | 1 BOTTLE, DROPPER in 1 CARTON (50090-1923-0) / 15 mL in 1 BOTTLE, DROPPER | July 15, 2015 |
| 24208-730-06 | 24208-730 | Bausch & Lomb Incorporated | 1 BOTTLE, DROPPER in 1 CARTON (24208-730-06) / 15 mL in 1 BOTTLE, DROPPER | September 29, 1995 |
| 70756-193-35 | 70756-193 | Lifestar Pharma LLC | 1 BOTTLE, DROPPER in 1 CARTON (70756-193-35) / 15 mL in 1 BOTTLE, DROPPER | May 21, 2025 |
| 42571-497-57 | 42571-497 | Micro Labs Limited | 1 BOTTLE in 1 CARTON (42571-497-57) / 15 mL in 1 BOTTLE | February 1, 2026 |
| 68071-4368-5 | 68071-4368 | NuCare Pharmaceuticals,Inc. | 15 mL in 1 BOX (68071-4368-5) | March 30, 2018 |
| 68071-5139-5 | 68071-5139 | NuCare Pharmaceuticals,Inc. | 15 mL in 1 BOTTLE (68071-5139-5) | December 23, 2019 |
| 70518-3408-0 | 70518-3408 | REMEDYREPACK INC. | 1 BOTTLE in 1 CARTON (70518-3408-0) / 15 mL in 1 BOTTLE | April 8, 2022 |
| 61314-016-01 | 61314-016 | Sandoz Inc. | 1 BOTTLE in 1 CARTON (61314-016-01) / 15 mL in 1 BOTTLE | June 5, 2000 |
| 70069-601-01 | 70069-601 | Somerset Therapeutics, LLC | 1 BOTTLE in 1 CARTON (70069-601-01) / 15 mL in 1 BOTTLE | October 10, 2024 |
| 85766-039-15 | 85766-039 | Sportpharm LLC | 1 BOTTLE in 1 CARTON (85766-039-15) / 15 mL in 1 BOTTLE | August 7, 2025 |
| 85766-056-15 | 85766-056 | Sportpharm LLC | 1 BOTTLE in 1 CARTON (85766-056-15) / 15 mL in 1 BOTTLE | August 22, 2025 |
| 85766-057-15 | 85766-057 | Sportpharm LLC | 1 BOTTLE, DROPPER in 1 CARTON (85766-057-15) / 15 mL in 1 BOTTLE, DROPPER | August 22, 2025 |
| 50090-1923 | 50090-1923 | A-S Medication Solutions | — | September 29, 1995 |
| 24208-730 | 24208-730 | Bausch & Lomb Incorporated | — | September 29, 1995 |
| 70756-193 | 70756-193 | Lifestar Pharma LLC | — | May 21, 2025 |
| 42571-497 | 42571-497 | Micro Labs Limited | — | February 1, 2026 |
| 68071-4368 | 68071-4368 | NuCare Pharmaceuticals,Inc. | — | September 29, 1995 |
| 68071-5139 | 68071-5139 | NuCare Pharmaceuticals,Inc. | — | October 19, 1973 |
| 70518-3408 | 70518-3408 | REMEDYREPACK INC. | — | April 8, 2022 |
| 61314-016 | 61314-016 | Sandoz Inc. | — | June 5, 2000 |
| 70069-601 | 70069-601 | Somerset Therapeutics, LLC | — | October 10, 2024 |
| 85766-039 | 85766-039 | Sportpharm LLC | — | October 10, 2024 |
| 85766-056 | 85766-056 | Sportpharm LLC | — | June 5, 2000 |
| 85766-057 | 85766-057 | Sportpharm LLC | — | September 29, 1995 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
| Enforcement | FDA | Recall records |
Generated September 25, 2026 · 12 sections on this page.